Dr. Penny Dacks, AFTD’s Chief Scientific Officer and President of the FTD Disorders Registry, and Dr. Shana Dodge, AFTD’s Director of Research Engagement attend the Clinical Trials in Alzheimer’s Disease (CTAD) meeting in San Diego in December 2025. The annual conference is an international event for researchers, industry leaders, and non-profits focused on developing new treatments for Alzheimer’s and related dementias, such as FTD. While there, AFTD staff presented on the capabilities of FTD Disorders Registry and how the Registry can be leveraged to support clinical trials in dementia. Learn more by reading Alzforum’s summary of key points from the conference.